Showing results (21-30 of 99) with videos related to
Sort By:
Pageof 10
CNS Spectrums|March 24, 2023
Lurasidone and risk of metabolic syndrome: results from short and long-term studies in patients with bipolar depressionMichael Tocco, John W Newcomer, Yongcai Mao, et al.Journal of General Internal Medicine|May 7, 2016
Diabetes and Cardiovascular Care Among People with Severe Mental Illness: A Literature ReviewChristina Mangurian, John W Newcomer, Chelsea Modlin, et al.Community Mental Health Journal|June 19, 2026
South Florida's Mobile Response Teams: Characteristics, Outcomes, and Implications for Behavioral Health Crisis CareSteven L Proctor, Ileana Cabrera, Danny Blanco, et al.BMC Health Services Research|April 6, 2018
Hospitalization outcomes in patients with schizophrenia after switching to lurasidone or quetiapine: a US claims database analysisJohn W Newcomer, Daisy Ng-Mak, Krithika Rajagopalan, et al.Current Medical Research and Opinion|July 10, 2018
Changes in metabolic parameters and body weight in brexpiprazole-treated patients with acute schizophrenia: pooled analyses of phase 3 clinical studiesJohn W Newcomer, Hans Eriksson, Peter Zhang, et al.Psychiatric Services (Washington, D.C.)|September 2, 2017
Understanding the Cost of a New Integrated Care Model to Serve CMHC Patients Who Have Serious Mental IllnessChristina Mangurian, Grace Niu, Dean Schillinger, et al.Current Opinion in Psychiatry|October 15, 2008
Addressing cardiometabolic risk during treatment with antipsychotic medicationsJonathan M Amiel, Christina V Mangurian, Rohan Ganguli, et al.CNS Spectrums|September 14, 2020
Lurasidone and risk for metabolic syndrome: results from short- and long-term clinical studies in patients with schizophreniaMichael Tocco, John W Newcomer, Yongcai Mao, et al.The Journal of Clinical Psychiatry|October 3, 2019
Changes in Metabolic Parameters and Body Weight in Patients With Major Depressive Disorder Treated With Adjunctive Brexpiprazole: Pooled Analysis of Phase 3 Clinical StudiesJohn W Newcomer, Hans Eriksson, Peter Zhang, et al.The Journal of Clinical Psychiatry|February 7, 2008
Prevalence of baseline serum glucose and lipid testing in users of second-generation antipsychotic drugs: a retrospective, population-based study of Medicaid claims dataElaine H Morrato, John W Newcomer, Richard R Allen, et al.Pageof 10